Preimplantation Genetic Testing for Aneuploidy (PGT-A)

Treatments

Book an Appointment

PGT-A | Preimplantation Genetic Testing for Aneuploidy

genetics

Advanced reproductive technology allows for embryos to be created through in vitro fertilization (IVF) and tested for chromosomal and genetic abnormalities. This testing gives fertility specialists the opportunity to select the healthiest embryos, with the greatest potential for implantation.

Preimplantation genetic testing for aneuplodity (PGT-A) counts the number of chromosomes in an embryo and can rule out abnormalities.

Who shouldconsider PGT-A?

To improve the chances of a successful pregnancy, individuals with certain risk factors may choose PGT-A to help identify the healthiest embryos. A fertility specialist might recommend it for:

  • Women 38 years or older who are using IVF to conceive.
  • Women who have experienced repeated IVF failures.
  • Women who have experienced three or more miscarriages in a row.

Genetic testing is a safe, non-invasive screening that doesn’t harm the embryo or increase pregnancy risks.

The processof PGT-A

genetics testing

IVF Canada’s lab team removes 5–7 cells from a mature embryo, sends them to our genetics lab for evaluation, and provides test results within 7–10 days.

Differences between Preimplantation genetic testing for aneuplodity (PGT-A) and Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M)

  • PGT-A (Preimplantation Genetic Testing for Aneuploidies): Screens embryos for abnormalities in the number of chromosomes (extra or missing copies), such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), or Turner syndrome (monosomy X).

  • PGT-M (Preimplantation Genetic Testing for Monogenic/Single Gene Defects): Looks for specific inherited single-gene disorders (mutations in one gene) such as Cystic Fibrosis, Sickle Cell Anemia, or Huntington’s disease.